CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Open platformOpen platform

Zai Lab's Zoci Shows 40% Response Rate in Trial of Previously Treated Extrapulmonary Neuroendocrine Cancers

By Public Technologies
  • Zai Lab’s Phase 1b/2 trial showed durable tumor responses to zocilurtatug pelitecan in previously treated advanced extrapulmonary neuroendocrine carcinomas.
  • Updated results will be presented November 6, 2026, at the North American Neuroendocrine Tumor Society symposium in Las Vegas.
  • Treatment showed a manageable safety profile, with few treatment-related discontinuations and no treatment-related deaths.
  • The company plans to pursue potential accelerated approval based on its single-arm expansion study, with topline data expected in 2027.
  • A global Phase 3 trial evaluating the drug as first-line maintenance monotherapy is expected to begin in 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zai Lab Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 202611050900BIZWIRE_USPR_____20261105_BW430679) on November 05, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk